High dose cisplatin after failure of polychemotherapy containing cisplatin in ovarian cancer. Preliminary results. Academic Article uri icon

Overview

abstract

  • A substantial percentage of patients with advanced ovarian cancer will progress or relapse after platinum-based front therapies and will require salvage chemotherapy. In order to evaluate feasibility and effectiveness of high dose platinum (HD-CDDP) nine patients with ovarian cancer were treated with HD-CDDP while progressing after conventional doses of the same drug. Cisplatin 40 mg/M2 d. 1----5 q. 28 days, was administered with forced chloruresis for a total of fifteen cycles. Preliminary results show a promising 44.4% response rate with acceptable toxicity: only one patient had to discontinue treatment because of severe combined toxicity including infection, mucositis, shaking tremors, ototoxicity and palmar hyperkeratosis.

publication date

  • April 1, 1985

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Cisplatin
  • Ovarian Neoplasms

Identity

Scopus Document Identifier

  • 0022415357

PubMed ID

  • 3891114

Additional Document Info

volume

  • 4

issue

  • 2